Literature DB >> 29068002

Engineered D2R Variants Reveal the Balanced and Biased Contributions of G-Protein and β-Arrestin to Dopamine-Dependent Functions.

Samuel J Rose1, Thomas F Pack1, Sean M Peterson1, Kaitlin Payne1, Emiliana Borrelli2, Marc G Caron1,3.   

Abstract

The dopamine D2 receptor (D2R), like many G-protein-coupled receptors, signals through G-protein- and β-arrestin-dependent pathways. Preferential activation of one of these pathways is termed functional selectivity or biased signaling and is a promising therapeutic strategy. Though biased signaling through D2Rs has been demonstrated, acquiring the mechanistic details of biased D2R/G-protein and D2R/β-arrestin signaling in vivo has been challenging because of the lack of techniques that specifically target these interactions in discrete cell populations. To address this question, we employed a cell type-specific viral expression approach to restore D2R variants that preferentially engage either G-protein or β-arrestin signaling in 'indirect pathway' medium spiny neurons (iMSNs), because of their central role in dopamine circuitry. We found that the effect of haloperidol antagonism on D2R metabolic signaling events is largely mediated by acute blockade of D2R/G-protein signaling. We show that a D2R-driven behavior, nestlet shredding, is similarly driven by D2R/G-protein signaling. On the other hand, D2R-driven locomotion and rearing require coordinated D2R/G-protein and D2R/β-arrestin signaling. The acute locomotor response to amphetamine and cocaine similarly depend on both G-protein and β-arrestin D2R signaling. Surprisingly, another psychotropic drug, phencyclidine, displayed a selective D2R/β-arrestin potentiation of locomotion. These findings highlight how D2R mostly relies upon balanced G-protein and β-arrestin signaling in iMSNs. However, the response to haloperidol and phencyclidine indicates that normal D2R signaling homeostasis can be dramatically altered, indicating that targeting a specific D2R signal transduction pathway could allow for more precise modulation of dopamine circuit function.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29068002      PMCID: PMC5854808          DOI: 10.1038/npp.2017.254

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  46 in total

1.  D1 and D2 dopamine receptor mRNA in rat brain.

Authors:  D M Weiner; A I Levey; R K Sunahara; H B Niznik; B F O'Dowd; P Seeman; M R Brann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

2.  Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32.

Authors:  Emmanuel Valjent; Jesus Bertran-Gonzalez; Heather Bowling; Sébastien Lopez; Emanuela Santini; Miriam Matamales; Alessandra Bonito-Oliva; Denis Hervé; Charles Hoeffer; Eric Klann; Jean-Antoine Girault; Gilberto Fisone
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

3.  Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats.

Authors:  E Carboni; A Imperato; L Perezzani; G Di Chiara
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

Review 4.  A psychomotor stimulant theory of addiction.

Authors:  R A Wise; M A Bozarth
Journal:  Psychol Rev       Date:  1987-10       Impact factor: 8.934

5.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.

Authors:  L M Bohn; R R Gainetdinov; F T Lin; R J Lefkowitz; M G Caron
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

7.  Nucleus accumbens dopamine/glutamate interaction switches modes to generate desire versus dread: D(1) alone for appetitive eating but D(1) and D(2) together for fear.

Authors:  Jocelyn M Richard; Kent C Berridge
Journal:  J Neurosci       Date:  2011-09-07       Impact factor: 6.167

8.  Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling.

Authors:  Julia C Lemos; Danielle M Friend; Alanna R Kaplan; Jung Hoon Shin; Marcelo Rubinstein; Alexxai V Kravitz; Veronica A Alvarez
Journal:  Neuron       Date:  2016-05-18       Impact factor: 17.173

9.  Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.

Authors:  Nikhil M Urs; Joshua C Snyder; Jacob P R Jacobsen; Sean M Peterson; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-27       Impact factor: 11.205

Review 10.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

View more
  12 in total

Review 1.  Disentangling the diverse roles of dopamine D2 receptors in striatal function and behavior.

Authors:  Eduardo F Gallo
Journal:  Neurochem Int       Date:  2019-02-01       Impact factor: 3.921

2.  Loss of β-arrestin2 in D2 cells alters neuronal excitability in the nucleus accumbens and behavioral responses to psychostimulants and opioids.

Authors:  Kirsten A Porter-Stransky; Alyssa K Petko; Saumya L Karne; L Cameron Liles; Nikhil M Urs; Marc G Caron; Carlos A Paladini; David Weinshenker
Journal:  Addict Biol       Date:  2019-08-23       Impact factor: 4.280

3.  Proteome-Informed Machine Learning Studies of Cocaine Addiction.

Authors:  Kaifu Gao; Dong Chen; Alfred J Robison; Guo-Wei Wei
Journal:  J Phys Chem Lett       Date:  2021-11-09       Impact factor: 6.888

4.  Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds.

Authors:  Elise Wouters; Jolien Walraed; Michael Joseph Robertson; Max Meyrath; Martyna Szpakowska; Andy Chevigné; Georgios Skiniotis; Christophe Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2019-11-04

5.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

6.  Residues and residue pairs of evolutionary importance differentially direct signaling bias of D2 dopamine receptors.

Authors:  María E Terrón-Díaz; Sara J Wright; Melina A Agosto; Olivier Lichtarge; Theodore G Wensel
Journal:  J Biol Chem       Date:  2019-11-01       Impact factor: 5.157

Review 7.  Emerging roles of striatal dopamine D2 receptors in motivated behaviour: Implications for psychiatric disorders.

Authors:  Pedro R Olivetti; Peter D Balsam; Eleanor H Simpson; Christoph Kellendonk
Journal:  Basic Clin Pharmacol Toxicol       Date:  2019-06-28       Impact factor: 4.080

Review 8.  Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sharonda S Harris; Nikhil M Urs
Journal:  CNS Drugs       Date:  2021-03-02       Impact factor: 5.749

Review 9.  How changes in dopamine D2 receptor levels alter striatal circuit function and motivation.

Authors:  Eleanor H Simpson; Eduardo F Gallo; Peter D Balsam; Jonathan A Javitch; Christoph Kellendonk
Journal:  Mol Psychiatry       Date:  2021-08-12       Impact factor: 13.437

10.  Signaling-Biased and Constitutively Active Dopamine D2 Receptor Variant.

Authors:  Dayana Rodriguez-Contreras; Alec F Condon; David C Buck; Naeem Asad; Timothy M Dore; Dineke S Verbeek; Marina A J Tijssen; Ujwal Shinde; John T Williams; Kim A Neve
Journal:  ACS Chem Neurosci       Date:  2021-05-11       Impact factor: 5.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.